MedTrace Logo

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

NCT04448223 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-06-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate efficacy and safety of CKD-351

Conditions

Interventions

DRUG

CKD-351

Latanoprost (25ug/ml), Dorzolamide (20mg/ml), twice a day

DRUG

Latanoprost+Dorzolmamide

Latanoprost(50ug/ml) , once a day Dorzolmamide(20mg/ml), threetimes a day

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • KiHo Park, MD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-11
Primary Completion
2022-12-05
Completion
2022-12-05

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04448223 on ClinicalTrials.gov